#United States #Robbins Geller #San Diego #Geron Corporation #Rytelo

Investors in Geron Corporation Face Class Action Opportunities

Recently, on April 26, 2025, Robbins Geller Rudman & Dowd LLP announced a significant opportunity for investors of Geron Corporation (NASDAQ: GERN) who experienced substantial losses between February 28, 2024, and February 25, 2025. The firm is inviting concerned investors to become lead plaintiffs in an ongoing class action lawsuit against Geron Corporation, which has been accused of violating provisions of the Securities Exchange Act of 1934.

Background of the Legal Action

The class action lawsuit, known as Dabestani v. Geron Corporation, is based on allegations that the company and certain executives made misleading statements regarding the performance and outlook of their flagship product, Rytelo. Known as a telomerase inhibitor, Rytelo has faced scrutiny since its rollout, particularly due to reports indicating slower-than-expected market penetration and sales growth.

During the class period, it is alleged that Geron gave investors an inaccurate impression of their growth potential by failing to sufficiently acknowledge the challenges posed by competition, market seasonality, and systematic economic factors. These factors have critically impacted patient adoption of Rytelo, especially among first-line use cases and within non-academic settings. The lawsuit suggests that executive teams 'downplayed risks' that were substantial to investor decision-making.

On February 26, 2025, Geron's financial results demonstrated the fallout from these issues, revealing that growth for Rytelo had considerably stagnated. The announcement stated that various external factors had led to a decline in expected results, prompting a sharp decrease of over 32% in the company's stock value, highlighting the disconnect between the company's professed performance and its actual market reception.

The Role of Potential Lead Plaintiffs

The Private Securities Litigation Reform Act of 1995 allows investors who purchased securities during the specified class period the right to seek appointment as lead plaintiff. This person, who must represent the interests of all affected investors, will guide the litigation process and select a law firm for further legal action – in this instance, Robbins Geller Rudman & Dowd LLP is poised to fulfill this role given its substantial expertise in investor rights and securities litigation.

Investors interested in taking on the role of lead plaintiff are urged to submit their information to the law firm by May 12, 2025, through the designated online portal. They can also reach out directly to attorneys involved for further guidance via phone or email.

The implication of becoming a lead plaintiff is significant. While it provides an opportunity to directly influence the lawsuit’s proceedings, it does not limit any investor's ability to recover losses unless they formally assume the role of lead plaintiff.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP holds a trusted name in the realm of securities litigation and investor representation. With a commendable track record of securing over $2.5 billion for investors over the past fiscal year alone, they continue to be a dominant force against corporate malfeasance in the financial sector. Their experienced attorneys have played pivotal roles in some of the largest securities class action recoveries, demonstrating their committed advocacy for shareholder rights.

For anyone who has dealt with losses from their investment in Geron Corporation and seeks to hold the company accountable, participating in this class action lawsuit could provide a viable path toward reparation. The focus is not merely on individual losses but rather on collective accountability of a corporation that has let its investors down.

Investors looking for more details on the case or wishing to participate should visit Robbins Geller's official page. They are encouraged to act promptly, as the timeline for submitting claims is tightly defined within the framework of this lawsuit.

If you’ve seen your investments in Geron suffer significantly, now is the moment to consider joining this legal effort – an opportunity that could facilitate recovery and hopefully restore some level of investor confidence.